Leap Therapeutics Stock Edges Higher After Recent Data
Decision brief
Answer first · skim in under a minute
Leap Therapeutics stock has seen a rise following recent clinical trial data. This article explores the implications for investors and pharmaceutical teams.
Leap Therapeutics Stock Edges Higher After Recent Data headlines should be tied to DeFianCe Phase 2 results for sirexatamab, not vague momentum. Final Part B data presented at ESMO 2025 showed biomarker-selected signals in MSS colorectal cancer, while the company also pursued strategic alternatives and later rebranding — facts investors must separate from a single-day move.
Contents9 sections
Key Takeaways
- DeFianCe (NCT05480306) Part B randomized 188 patients with second-line microsatellite-stable colorectal cancer to sirexatamab plus bevacizumab/chemotherapy versus control.
- At ESMO 2025, Leap reported statistically significant ORR and PFS benefit in patients with high circulating DKK1, with a positive trend in the intent-to-treat population.
- In the ITT analysis cited in the October 20, 2025 release, ORR was 35.1% versus 26.6% and median PFS was 9.2 versus 8.3 months (HR 0.84; p=0.1712).
- Sirexatamab is not FDA-approved; the company described later regulatory pathway discussions and major corporate restructuring.
What did the DeFianCe data actually show?
Sirexatamab (DKN-01) is an anti-DKK1 monoclonal antibody. DeFianCe Part B compared sirexatamab plus bevacizumab and chemotherapy with bevacizumab and chemotherapy alone in MSS CRC after one prior systemic therapy for advanced disease. The primary objective was progression-free survival; secondary objectives included ORR, duration of response, and overall survival. High circulating DKK1 was a key predefined exploratory population.
Company-reported final Part B results presented October 20, 2025 at ESMO included a statistically significant benefit on ORR and PFS in high-DKK1 patients and a positive trend on ORR and PFS in the full ITT population. ITT figures cited include ORR 35.1% versus 26.6% and median PFS 9.2 versus 8.3 months (HR 0.84; p=0.1712), with event-free rates favoring the sirexatamab arm at month 9 and month 12 in the company's summary.
Sources: October 20, 2025 PR Newswire ESMO data release and ClinicalTrials.gov NCT05480306.
Why stock narratives need corporate context
On June 23, 2025, Leap reported updated DeFianCe data and said its board was exploring strategic alternatives amid cash conservation steps, including a planned workforce reduction of about 75% with estimated related costs around $3.2 million and cash of $32.7 million as of March 31, 2025. Later SEC filings and wires describe wind-down of research activities and a corporate shift in which Cypherpunk Technologies (formerly Leap Therapeutics) reported continuing evaluation of a sirexatamab registrational pathway through a Leap subsidiary while changing capital strategy.
That means a ticker move after “recent data” can reflect short-interest dynamics, restructuring headlines, or residual oncology optionality — not a clean binary on FDA approval.
Context wire: June 23, 2025 PR Newswire update and strategic alternatives.
What BD teams should diligence next
- Biomarker assay maturity for selecting high-DKK1 CRC patients
- Whether regulators accept a biomarker-enriched Phase 3 design
- Ownership and funding of any remaining oncology program after restructuring
- Whether ITT PFS (non-significant at p=0.1712 in company ITT summary) can support a broad label thesis
Do not treat ESMO presentation slides as an FDA approval. Do not invent intradaily percentage moves without a contemporaneous exchange print citation.
Data points
- Part A: 33 patients; Part B: 188 patients randomized
- Population: second-line MSS CRC
- Combination: sirexatamab + bevacizumab + chemotherapy
- ITT mPFS: 9.2 vs 8.3 months (HR 0.84; p=0.1712)
- Registry: NCT05480306
What remains unproven
Overall survival maturity, registrational study design agreement with FDA/EMA, and commercial viability after corporate restructuring remain open. High-DKK1 subset wins do not automatically generalize to all MSS CRC patients.
Related NovaPharma coverage
- Friday Five clinical trial catalysts
- FDA atezolizumab MIBC approval coverage
- FDA clinical trial process updates
Frequently Asked Questions
What clinical data moved Leap Therapeutics into focus?
Leap presented final Part B DeFianCe Phase 2 data for sirexatamab (DKN-01) plus bevacizumab and chemotherapy in second-line MSS colorectal cancer at ESMO 2025, including statistically significant ORR and PFS benefit in high-DKK1 patients.
What is the DeFianCe trial ID and size?
DeFianCe is NCT05480306. Part B was a 188-patient randomized controlled trial after a 33-patient Part A.
Did FDA approve sirexatamab?
No. Company communications describe engagement with regulators on a potential registrational pathway; that is not marketing approval.
Primary Sources
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
